India, April 16 -- TG Therapeutics Inc. (TGTX), a commercial-stage biotechnology company, announced on Wednesday the completion of enrollment in its Phase 3 trial evaluating subcutaneous BRIUMVI for the treatment of relapsing forms of multiple sclerosis.
Relapsing forms of multiple sclerosis (RMS) is a chronic, autoimmune, demyelinating disease of the central nervous system (CNS). It is estimated that over 1 million people live with MS in the U.S., and more than 2.3 million worldwide.
BRIUMVI (ublituximab-xiiy), a monoclonal antibody targeting a unique epitope on CD20-expressing B-cells, is approved by the U.S. FDA as a one-hour intravenous (IV) infusion for adults with RMS.
The Phase 3 trial is a non-inferiority, randomized, open-label,...